Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.1K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic and imaging phenotypes associated with RB1 and TP53 loss in prostate cancer.

Neoplasia (New York, N.Y.)·2025
Same author

Metabolic and imaging phenotypes associated with <i>RB1</i> and <i>TP53</i> loss in prostate cancer.

bioRxiv : the preprint server for biology·2025
Same author

Monitoring response to a clinically relevant IDH inhibitor in glioma-Hyperpolarized <sup>13</sup>C magnetic resonance spectroscopy approaches.

Neuro-oncology advances·2023
Same author

Mitoribosome sensitivity to HSP70 inhibition uncovers metabolic liabilities of castration-resistant prostate cancer.

PNAS nexus·2023
Same author

DHODH inhibition impedes glioma stem cell proliferation, induces DNA damage, and prolongs survival in orthotopic glioblastoma xenografts.

Oncogene·2022
Same author

LXRβ controls glioblastoma cell growth, lipid balance, and immune modulation independently of ABCA1.

Scientific reports·2019

Related Experiment Video

Updated: Oct 28, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K

Metabolic reprogramming in prostate cancer.

Fahim Ahmad1,2, Murali Krishna Cherukuri3, Peter L Choyke4

  • 1Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. fahim.ahmad@nih.gov.

British Journal of Cancer
|July 15, 2021
PubMed
Summary

Metastatic prostate cancer is incurable due to treatment resistance. Understanding prostate cancer metabolism and its reprogramming may lead to more durable therapeutic responses.

More Related Videos

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging
11:43

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging

Published on: December 30, 2016

10.7K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.0K

Related Experiment Videos

Last Updated: Oct 28, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K
Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging
11:43

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging

Published on: December 30, 2016

10.7K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.0K

Area of Science:

  • Oncology
  • Metabolic Research

Background:

  • Localized prostate cancer has good prognosis with treatments like surgery and radiation.
  • Metastatic prostate cancer remains incurable, with current therapies facing resistance and poor outcomes.
  • Treatment resistance is driven by tumor heterogeneity, genetic changes, and metabolic reprogramming.

Purpose of the Study:

  • To review alterations in prostate cancer metabolism.
  • To explore genetic signatures and molecular pathways linked to metabolic reprogramming in prostate cancer.
  • To connect understanding of prostate cancer metabolism to therapeutic resistance.

Main Methods:

  • Literature review focusing on prostate cancer metabolism.
  • Analysis of genetic signatures and molecular pathways involved in metabolic reprogramming.
  • Examination of adaptive responses to therapy driven by metabolic changes.

Main Results:

  • Prostate cancer cells adapt to therapy through metabolic reprogramming.
  • Tumor heterogeneity and genetic alterations contribute to treatment resistance.
  • Specific molecular pathways are associated with altered cancer metabolism.

Conclusions:

  • Understanding prostate cancer metabolism is crucial for overcoming treatment resistance.
  • Targeting metabolic reprogramming may enhance therapeutic durability.
  • Further research into cancer metabolism could yield improved treatment strategies.